CLINICAL TRIALS PROFILE FOR ZIPRASIDONE MESYLATE

All Clinical Trials for ziprasidone mesylate

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT02935998 ↗	The Efficacy And Safety Of Intramuscular Ziprasidone For Three Days In Patients With Psychotic Agitation	Unknown status	Pfizer	Phase 4	2016-10-01	1. The title of this study is a multi-center,non randomized,open-labeled,intervention study:the efficacy and safety of intramuscular ziprasidone for three days in patients with acute psychotic agitation. 2. The primary objectiveis to evaluate the efficacy of intramuscular ziprasidone in patients with acute psychotic agitation in daily clinical practice. 3. The secondary objectives are:1.To evaluate the safety of intramuscular ziprasidone in patients with acute psychotic agitation in daily clinical practice.2.To compare the efficacy and tolerance of intramuscular ziprasidone in patients with agitation in the different psychotic disorder 3.To compare the efficacy and tolerance of intramuscular ziprasidone in patients with first episode andmulti-episode patients. 4.To explore the measured based administration according to severity of symptoms.5.To compare the efficacy and tolerance of ziprasidone im between the monotherapy and combination with other antipsychotic drug in clinical practice. 4. The Rationale:In China, the studies of ziprasidone im treating agitation focus on schizophrenia. But in the foreign country, ziprasidone im also is approved to treat psychotic agitation, including bipolar and schizoaffective disorder. And in the clinical practice of China, ziprasidone im is also used to treat other patients, although the evidence is less. In this study, we assume ziprasidone im treat the psychotic agitation is effective and safe. 5. Study populations:The study plan to enroll 1000 subjects in China. （6）The background and the hypothesis：The researches of ziprasidone mesylate injection in our country are more concentrated in schizophrenia at present, while in foreign countries ziprasidone is approved for psychotic agitation, including mania etc. It's also used for substance abuse and alcohol induced agitation.Therefore, this study assumes that ziprasidone mesylate injection is effective in the treatment of acute agitation, and it's well tolerated.
NCT02935998 ↗	The Efficacy And Safety Of Intramuscular Ziprasidone For Three Days In Patients With Psychotic Agitation	Unknown status	Yang Fude	Phase 4	2016-10-01	1. The title of this study is a multi-center,non randomized,open-labeled,intervention study:the efficacy and safety of intramuscular ziprasidone for three days in patients with acute psychotic agitation. 2. The primary objectiveis to evaluate the efficacy of intramuscular ziprasidone in patients with acute psychotic agitation in daily clinical practice. 3. The secondary objectives are:1.To evaluate the safety of intramuscular ziprasidone in patients with acute psychotic agitation in daily clinical practice.2.To compare the efficacy and tolerance of intramuscular ziprasidone in patients with agitation in the different psychotic disorder 3.To compare the efficacy and tolerance of intramuscular ziprasidone in patients with first episode andmulti-episode patients. 4.To explore the measured based administration according to severity of symptoms.5.To compare the efficacy and tolerance of ziprasidone im between the monotherapy and combination with other antipsychotic drug in clinical practice. 4. The Rationale:In China, the studies of ziprasidone im treating agitation focus on schizophrenia. But in the foreign country, ziprasidone im also is approved to treat psychotic agitation, including bipolar and schizoaffective disorder. And in the clinical practice of China, ziprasidone im is also used to treat other patients, although the evidence is less. In this study, we assume ziprasidone im treat the psychotic agitation is effective and safe. 5. Study populations:The study plan to enroll 1000 subjects in China. （6）The background and the hypothesis：The researches of ziprasidone mesylate injection in our country are more concentrated in schizophrenia at present, while in foreign countries ziprasidone is approved for psychotic agitation, including mania etc. It's also used for substance abuse and alcohol induced agitation.Therefore, this study assumes that ziprasidone mesylate injection is effective in the treatment of acute agitation, and it's well tolerated.

Clinical Trial Conditions for ziprasidone mesylate

Condition Name

Condition Name for ziprasidone mesylate
Intervention	Trials
Schizophrenia	1

Condition MeSH

Condition MeSH for ziprasidone mesylate
Intervention	Trials
Schizophrenia	1
Psychomotor Agitation	1

Clinical Trial Locations for ziprasidone mesylate

Trials by Country

Trials by Country for ziprasidone mesylate
Location	Trials
China	1

Clinical Trial Progress for ziprasidone mesylate

Clinical Trial Phase

Clinical Trial Phase for ziprasidone mesylate
Clinical Trial Phase	Trials
Phase 4	1

Clinical Trial Status

Clinical Trial Status for ziprasidone mesylate
Clinical Trial Phase	Trials
Unknown status	1

Clinical Trial Sponsors for ziprasidone mesylate

Sponsor Name

Sponsor Name for ziprasidone mesylate
Sponsor	Trials
Pfizer	1
Yang Fude	1

Sponsor Type

Sponsor Type for ziprasidone mesylate
Sponsor	Trials
Industry	1
Other	1

Ziprasidone mesylate Market Analysis and Financial Projection

Last updated: May 1, 2026

Ziprasidone Mesylate: Clinical-Stage Update, Market View, and Forward Projections

Ziprasidone mesylate is an established antipsychotic with a branded history (notably Geodon). Current market performance is driven by (1) ongoing generic penetration, (2) residual brand demand where payers prefer lowest net-cost alternatives, and (3) the clinical and safety position of ziprasidone within schizophrenia and bipolar disorder care pathways. Patent/market exclusivity dynamics are determinative of near-term brand economics; clinical “updates” are largely restricted to label-maintenance and comparative/real-world studies rather than new, late-stage registrations.

What is the current clinical-trial and regulatory posture for ziprasidone mesylate?

Ziprasidone mesylate is not in a development phase where meaningful, sponsor-level late-stage trials are expected to reshape the label. Activity in the clinical trial landscape is dominated by post-marketing studies, comparative effectiveness work, pharmacovigilance, and real-world evidence. Trial volume tends to remain steady but is not typically associated with new mechanism-of-action or new populations reaching approval milestones.

What this means for a clinical-trials “update”

• Expect incremental evidence streams (adherence, persistence, safety signals, comparative outcomes).
• Expect limited probability of label expansion that would materially change market size in major geographies.
• Expect that any trial-based market impact is mostly secondary to pricing and formulary decisions.

Key regulatory/label anchor (clinical relevance)

• Ziprasidone is approved for schizophrenia and bipolar disorder indications in core markets under the ziprasidone (mesylate salt) product family (e.g., oral formulations; formulations and indications vary by country).
• The market’s leading use-cases remain those indications, with prescribing shaped by efficacy profile and QT-related risk management practices.

Where does ziprasidone mesylate sit in the market now?

Ziprasidone’s market reality is “mature branded product + broad generics.” Brand economics depend on sustained payer acceptance and net pricing, while unit share depends on formulary placement relative to lower-cost antipsychotic options.

US payer and channel dynamics that typically govern share

• Formulary placement in schizophrenia/bipolar disorder is heavily influenced by net price and preferred-generic status.
• Comparative prescribing behavior often clusters around “cost-effectiveness plus patient tolerability,” with clinicians weighing sedation, weight/metabolic risk, and QT considerations.

Competitive set (practical substitution risk) Ziprasidone is frequently evaluated against:

• Metabolic-favorable or weight-neutral antipsychotics (for payer and clinician preference).
• Lower-cost generic competitors.
• Long-acting injectable alternatives where adherence is a major constraint.

The core commercial constraint

• As generics dominate, brand value becomes a function of staying power (contracts, patient re-challenge after tolerability issues, and prescriber familiarity) rather than new prescribing drivers.

What market projections can be modeled for ziprasidone mesylate?

A defensible projection framework for ziprasidone mesylate must reflect three forces:

1. Generic substitution: persistent downward pressure on branded unit economics.
2. Net pricing: brand and payer rebates stabilize some revenue but rarely reverse long-run erosion.
3. Therapy demand: schizophrenia and bipolar prevalence growth supports base demand, but it is shared across a crowded, mature class.

Because ziprasidone is mature, the highest-value projection variables are market-level revenue retention and erosion rates, not scenario-changing clinical catalysts. Without a current late-stage “registration tailwind,” the likely path is gradual decline in branded revenue with slower decline in total (branded + generic) unit volumes if adherence and clinician preference hold.

Projection direction (base case)

• Branded ziprasidone mesylate revenue: continues to erode gradually due to generic penetration and formulary migration to lower-cost options.
• Total class share for ziprasidone: stays relatively stable in the near term, supported by prescriber-specific fit (tolerability/QT-management alignment), but does not expand materially because of limited label expansion.

Projection logic by horizon

• Short term (0 to 24 months): stable units, continued branded revenue pressure from price compression.
• Mid term (2 to 5 years): slower decline in branded revenue; total prescriptions may hold or drift with patient-level switching dynamics.
• Long term (5+ years): market normalization at predominantly generic pricing; any meaningful growth requires a regulatory label change or new differentiated formulation.

Where are the clinical evidence “signals” that matter commercially?

In mature antipsychotics, clinical impact is typically channeled into:

• Safety positioning (especially QT monitoring strategy and risk mitigation language).
• Tolerability and adherence patterns, including persistence.
• Comparative effectiveness in real-world datasets versus competitors.

The commercial “signal” is not a new efficacy claim that expands the addressable population. Instead, it is whether payers and clinicians justify continued use where cost is not the lowest, often because safety monitoring is manageable and patient tolerability is acceptable.

What do stakeholders likely prioritize next for R&D or investment decisions?

Given the market maturity, decision-making tends to pivot to product-line optimization and lifecycle management rather than core-development breakthroughs.

Highest-leverage R&D themes (typical for mature antipsychotics)

• Formulation or delivery refinements that reduce discontinuation or improve tolerability.
• Evidence generation targeted at payer decision points (persistence, hospitalization rates, adherence).
• Data that supports subpopulation use where ziprasidone’s risk-benefit profile is favored.

What would create a material label-driven market inflection

• A new indication, new population, or new regimen that triggers payer reclassification.
• A new delivery format with clear adherence or safety advantage and regulatory acceptance. Absent those, the market impact stays pricing- and access-driven.

---

Market and Clinical Summary Table

Dimension	Current state for ziprasidone mesylate	Market implication
Clinical stage	Post-marketing evidence and incremental comparative work dominate	Low probability of label-driven market expansion
Regulatory position	Established approvals for schizophrenia and bipolar indications in major markets	Addressable population is fixed; growth depends on share retention
Competitive intensity	High generic penetration and crowded antipsychotic class	Branded revenue erosion persists
Differentiation	Clinical practice fit shaped by efficacy-tolerability balance and QT risk management	Supports niche persistence, not broad category expansion
Commercial driver	Formulary and net pricing	Revenue declines slower than units only if net price stabilizes

---

Key Takeaways

• Ziprasidone mesylate is a mature antipsychotic with clinical activity centered on post-marketing evidence rather than new label-defining late-stage trials.
• The market outlook is primarily determined by generic penetration, formulary placement, and net pricing, not by imminent clinical catalysts.
• Near- to mid-term projections favor stabilization of total prescriptions with continued decline in branded revenue as price compression persists.
• Material upside requires differentiated lifecycle events (new formulation, label expansion, or strong payer-facing comparative outcomes), which are not the dominant pattern for this asset at present.

---

FAQs

1) Is ziprasidone mesylate currently in late-stage clinical development for a new indication?
Clinical activity is primarily post-marketing and comparative; the asset is not characterized by new late-stage registration patterns that typically drive label expansion.

2) What drives ziprasidone prescribing today in schizophrenia and bipolar disorder?
Prescriber and payer decisions rely on efficacy-tolerability fit, practical QT risk management, and patient-specific response after switching.

3) How does generic competition affect ziprasidone mesylate’s revenue outlook?
Generic penetration drives sustained branded revenue compression; it also increases price transparency and shifts formulary decisions toward lowest net-cost options.

4) What evidence types matter most for commercial positioning of an established antipsychotic?
Real-world persistence, discontinuation, hospitalization proxies, and safety/risk-mitigation outcomes that align with payer decision frameworks.

5) What is the most realistic path to upside for ziprasidone mesylate?
Lifecycle differentiation (new formulation/regimen) or a new label expansion with clear payer-relevant differentiation, rather than incremental comparative studies alone.

---

References (APA)

[1] U.S. Food and Drug Administration. (n.d.). Drug trials snapshots: Ziprasidone. https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots
[2] U.S. Food and Drug Administration. (n.d.). Drug labels and prescribing information (ziprasidone mesylate/geodon related product information). https://www.accessdata.fda.gov/scripts/cder/daf/
[3] ClinicalTrials.gov. (n.d.). Ziprasidone mesylate clinical trials. https://clinicaltrials.gov/